Cite
HARVARD Citation
Herbst, R. et al. (2018). Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet oncology. 19 (1), pp. 101-114. [Online].